{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:05:09Z","timestamp":1772136309084,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Foundation of Korea (NRF), Ministry of Education","award":["NRF-2022R1A2C1093325"],"award-info":[{"award-number":["NRF-2022R1A2C1093325"]}]},{"name":"National Research Foundation of Korea (NRF), Ministry of Education","award":["NRF-2022R1A2C1093325"],"award-info":[{"award-number":["NRF-2022R1A2C1093325"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-09352-w","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:56:14Z","timestamp":1758884174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Achieved targeted heart rate following ivabradine therapy correlates with left ventricular reverse remodeling in non-ischemic dilated cardiomyopathy"],"prefix":"10.1038","volume":"15","author":[{"given":"Jooyeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaehyung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"9352_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"9352_CR2","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145, e895\u2013e1032 (2022).","journal-title":"Circulation"},{"key":"9352_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.36628\/ijhf.2023.0011","volume":"5","author":"J-C Youn","year":"2023","unstructured":"Youn, J.-C. et al. Korean society of heart failure guidelines for the management of heart failure: Treatment. Int. J. Heart Fail. 5, 66\u201381 (2023).","journal-title":"Int. J. Heart Fail."},{"key":"9352_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","volume":"76","author":"JE Wilcox","year":"2020","unstructured":"Wilcox, J. E., Fang, J. C., Margulies, K. B. & Mann, D. L. Heart failure with recovered left ventricular ejection fraction: JACC scientific expert panel. J. Am. Coll. Cardiol. 76, 719\u2013734 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"9352_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jchf.2019.06.004","volume":"7","author":"A Aimo","year":"2019","unstructured":"Aimo, A., Gaggin, H. K., Barison, A., Emdin, M. & Januzzi, J. L. Jr. Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail. 7, 782\u2013794 (2019).","journal-title":"JACC Heart Fail."},{"key":"9352_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11897-021-00501-6","volume":"18","author":"A Abboud","year":"2021","unstructured":"Abboud, A. & Januzzi, J. L. Reverse cardiac remodeling and ARNI therapy. Curr. Heart Fail. Rep. 18, 71\u201383 (2021).","journal-title":"Curr. Heart Fail. Rep."},{"key":"9352_CR7","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1002\/ehf2.13483","volume":"8","author":"R Rasalam","year":"2021","unstructured":"Rasalam, R. et al. Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: Systematic review. ESC Heart Fail. 8, 4093\u20134118 (2021).","journal-title":"ESC Heart Fail."},{"key":"9352_CR8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"M B\u00f6hm","year":"2010","unstructured":"B\u00f6hm, M. et al. Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376, 886\u2013894 (2010).","journal-title":"Lancet"},{"key":"9352_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 376, 875\u2013885 (2010).","journal-title":"Lancet"},{"key":"9352_CR10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"32","author":"JC Tardif","year":"2011","unstructured":"Tardif, J. C. et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur. Heart J. 32, 2507\u20132515 (2011).","journal-title":"Eur. Heart J."},{"key":"9352_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijcard.2010.10.125","volume":"146","author":"C Ceconi","year":"2011","unstructured":"Ceconi, C. et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of beautiful. Int. J. Cardiol. 146, 408\u2013414 (2011).","journal-title":"Int. J. Cardiol."},{"key":"9352_CR12","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui, H. et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure- J-SHIFT study. Circ. J. 83, 2049\u20132060 (2019).","journal-title":"Circ. J."},{"key":"9352_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jacc.2022.05.027","volume":"80","author":"F Ye","year":"2022","unstructured":"Ye, F. et al. Sustained-release ivabradine hemisulfate in patients with systolic heart failure. J. Am. Coll. Cardiol. 80, 584\u2013594 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"9352_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/oxfordjournals.eurheartj.a060471","volume":"15","author":"G Hasenfuss","year":"1994","unstructured":"Hasenfuss, G. et al. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur. Heart J. 15, 164\u2013170 (1994).","journal-title":"Eur. Heart J."},{"key":"9352_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/01.CIR.86.2.513","volume":"86","author":"RP Kelly","year":"1992","unstructured":"Kelly, R. P. et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation 86, 513\u2013521 (1992).","journal-title":"Circulation"},{"key":"9352_CR16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","volume":"283","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson, A. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF) MERIT-HF study group. JAMA 283, 1295\u20131302 (2000).","journal-title":"JAMA"},{"key":"9352_CR17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer, M. et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651\u20131658 (2001).","journal-title":"N. Engl. J. Med."},{"key":"9352_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"PF Lechat","year":"1999","unstructured":"Lechat, P. F. et al. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet 353, 9\u201313 (1999).","journal-title":"Lancet"},{"key":"9352_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1253\/circj.CJ-16-0101","volume":"80","author":"H-Y Lee","year":"2016","unstructured":"Lee, H.-Y. & Baek, S. H. Optimal use of beta-blockers for congestive heart failure. Circ. J. 80, 565\u2013571 (2016).","journal-title":"Circ. J."},{"key":"9352_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019240","volume":"10","author":"N Enzan","year":"2021","unstructured":"Enzan, N. et al. Beta-blocker use is associated with prevention of left ventricular remodeling in recovered dilated cardiomyopathy. J. Am. Heart Assoc. 10, e019240 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"9352_CR21","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/ejhf.2870","volume":"25","author":"M B\u00f6hm","year":"2023","unstructured":"B\u00f6hm, M. et al. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction. Eur. J. Heart Fail. 25, 1429\u20131435 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"9352_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1085\/jgp.20028593","volume":"120","author":"A Bucchi","year":"2002","unstructured":"Bucchi, A., Baruscotti, M. & DiFrancesco, D. Current-dependent block of rabbit sino-atrial node if channels by ivabradine. J. Gen. Physiol. 120, 1\u201313 (2002).","journal-title":"J. Gen. Physiol."},{"key":"9352_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jchf.2018.11.011","volume":"7","author":"PA Peri-Okonny","year":"2019","unstructured":"Peri-Okonny, P. A. et al. Target doses of heart failure medical therapy and blood pressure: Insights from the CHAMP-HF registry. JACC Heart Fail. 7, 350\u2013358 (2019).","journal-title":"JACC Heart Fail."},{"key":"9352_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.36628\/ijhf.2019.0007","volume":"1","author":"J Oh","year":"2019","unstructured":"Oh, J. et al. Real-world eligibility for Sacubitril\/Valsartan in heart failure with reduced ejection fraction patients in Korea: Data from the Korean acute heart failure (KorAHF) registry. Int. J. Heart Fail. 1, 57\u201368 (2019).","journal-title":"Int. J. Heart Fail."},{"key":"9352_CR25","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/ehf2.13837","volume":"9","author":"J Oh","year":"2022","unstructured":"Oh, J. et al. Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction. ESC Heart Fail. 9, 1492\u20131495 (2022).","journal-title":"ESC Heart Fail."},{"key":"9352_CR26","doi-asserted-by":"publisher","first-page":"H435","DOI":"10.1152\/ajpheart.00591.2008","volume":"296","author":"P Milliez","year":"2009","unstructured":"Milliez, P. et al. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 296, H435\u2013H441 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"9352_CR27","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1002\/ehf2.14455","volume":"10","author":"A Abdin","year":"2023","unstructured":"Abdin, A. et al. Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial). ESC Heart Fail. 10, 2895\u20132902 (2023).","journal-title":"ESC Heart Fail."},{"key":"9352_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2261-14-150","volume":"14","author":"S-L Chen","year":"2014","unstructured":"Chen, S.-L., Hu, Z.-Y., Zuo, G.-F., Li, M.-H. & Li, B. I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice. BMC Cardiovasc. Disord. 14, 150 (2014).","journal-title":"BMC Cardiovasc. Disord."},{"key":"9352_CR29","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1111\/bph.13220","volume":"172","author":"P Kleinbongard","year":"2015","unstructured":"Kleinbongard, P. et al. Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br. J. Pharmacol. 172, 4380\u20134390 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"9352_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1010-7940(02)00359-7","volume":"22","author":"JD Mule","year":"2002","unstructured":"Mule, J. D. et al. The beneficial effect of revascularization on jeopardized myocardium: Reverse remodeling and improved long-term prognosis. Eur. J. Cardiothorac. Surg. 22, 426\u2013430 (2002).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"9352_CR31","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/ehf2.13939","volume":"9","author":"T Hnat","year":"2022","unstructured":"Hnat, T., Veselka, J. & Honek, J. Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy. ESC Heart Fail. 9, 2070\u20132083 (2022).","journal-title":"ESC Heart Fail."},{"key":"9352_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jacc.2017.11.020","volume":"71","author":"E Sze","year":"2018","unstructured":"Sze, E. et al. Impaired recovery of left ventricular function in patients with cardiomyopathy and left bundle branch block. J. Am. Coll. Cardiol. 71, 306\u2013317 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"9352_CR33","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1001\/jama.299.22.2656","volume":"299","author":"NC Wang","year":"2008","unstructured":"Wang, N. C. et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 299, 2656\u20132666 (2008).","journal-title":"JAMA"},{"key":"9352_CR34","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","volume":"83","author":"M Maddox Thomas","year":"2024","unstructured":"Maddox Thomas, M. et al. ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction. J. Am. Coll. Cardiol. 83, 1444\u20131488 (2024).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09352-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09352-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09352-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:56:14Z","timestamp":1758884174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09352-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9352"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09352-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5425737\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest and declare no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33043"}}